- Rich Pharmaceuticals.com Medical Professionals Protected: Trial Participation
Protected: Trial Participation
Medical Professionals
News
April 10th, 2018
Rich Pharmaceuticals Explains How Targeted Immunotherapy Aids in the Treatment and Recovery of AML Patients
View Release
March 14th, 2018
Rich Pharmaceuticals’ Study Drug RP-323 (TPA) is a Potential Therapeutic Agent for the Treatment of Hodgkin’s Lymphoma
View Release
March 6th, 2018
Rich Pharmaceuticals’ Study Drug RP-323 (TPA) Elevates White Blood Cells (WBCs) Which Play a Vital Role Fighting Infections, and in Immunotherapy
View Release